This session reviewed the development of strategies to identify patients at higher risk of having a recurrence of their leukemia. Contemporary criteria used in the Children’s Oncology Group trials for allocation to different risk groups for patients with acute lymphoblastic leukemia was reviewed. Modifications of therapy based on risk assignment were summarized.
Sarah Alexander, MD
Clinical Director, Haematology/Oncology
Hospital for Sick Children, Toronto